- Home
- BOLT
as 07-26-2024 4:00pm EST
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 28.6M | IPO Year: | 2021 |
| Target Price: | $1.25 | AVG Volume (30 days): | 114.9K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $1.56 | Next Earning Date: | 08-05-2024 |
| Revenue: | $11,324,000 | Revenue Growth: | 67.96% |
| Revenue Growth (this year): | 15.66% | Revenue Growth (next year): | -54.43% |
Stock Insider Trading Activity of Bolt Biotherapeutics Inc. (BOLT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Quinn William P. | BOLT | Chief Financial Officer | Dec 12 '23 | Buy | $1.18 | 1,829 | $2,160.96 | 26,272 | SEC Form 4 |
| Quinn William P. | BOLT | Chief Financial Officer | Dec 12 '23 | Buy | $0.78 | 2,500 | $1,955.00 | 28,772 | SEC Form 4 |
| Quinn William P. | BOLT | Chief Financial Officer | Dec 12 '23 | Buy | $0.95 | 7,500 | $7,125.00 | 36,272 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 29 '23 | Sell | $0.91 | 22,674 | $20,542.64 | 1,929,628 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 29 '23 | Sell | $0.86 | 108,145 | $92,799.22 | 1,821,483 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 29 '23 | Sell | $0.91 | 3,131 | $2,836.69 | 266,456 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 29 '23 | Sell | $0.86 | 14,934 | $12,814.87 | 251,522 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 21 '23 | Sell | $0.90 | 1,707 | $1,536.30 | 1,952,302 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 21 '23 | Sell | $0.90 | 236 | $212.40 | 269,587 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 21 '23 | Sell | $0.90 | 1,457 | $1,311.30 | 111,662 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 16 '23 | Sell | $0.96 | 7,531 | $7,229.76 | 1,989,685 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 16 '23 | Sell | $0.93 | 8,211 | $7,636.23 | 1,981,474 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 16 '23 | Sell | $0.92 | 27,465 | $25,267.80 | 1,954,009 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 16 '23 | Sell | $0.96 | 1,040 | $998.40 | 274,749 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 16 '23 | Sell | $0.93 | 1,134 | $1,054.62 | 273,615 | SEC Form 4 |
| ENGLEMAN EDGAR | BOLT | Director | Nov 16 '23 | Sell | $0.92 | 3,792 | $3,488.64 | 269,823 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.96 | 7,531 | $7,229.76 | 1,989,685 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.96 | 1,040 | $998.40 | 274,749 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.96 | 6,429 | $6,171.84 | 143,571 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.93 | 8,211 | $7,636.23 | 1,981,474 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.93 | 1,134 | $1,054.62 | 273,615 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.93 | 7,009 | $6,518.37 | 136,562 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.92 | 27,465 | $25,267.80 | 1,954,009 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.92 | 3,792 | $3,488.64 | 269,823 | SEC Form 4 |
| Vivo Capital VIII, LLC | BOLT | 10% Owner | Nov 16 '23 | Sell | $0.92 | 23,443 | $21,567.56 | 113,119 | SEC Form 4 |
Latest Bolt Biotherapeutics Inc. News
BOLT Breaking Stock News: Dive into BOLT Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 months ago
Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...
MT Newswires
2 months ago
Top Midday Decliners
BioPharma Dive
2 months ago
Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate
GlobeNewswire
2 months ago
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
Simply Wall St.
3 months ago
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
GlobeNewswire
4 months ago
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
GlobeNewswire
5 months ago
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Associated Press Finance
6 months ago
Old Point Financial: Q4 Earnings Snapshot
Compare BOLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BOLT Bolt Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.